Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (3405)	6/2/2013 12:07:17 PM
From: richardred	Respond to of 7239

India's Sun Pharmaceuticals Readies $5 Billion Deal for Sweden's Meda RE: B& L Just days ago it made a failed bid for eye-products maker Bausch & Lomb online.wsj.com

To: richardred who wrote (3405)	12/16/2013 11:49:34 AM
From: richardred	Read Replies (1) \| Respond to of 7239

Bolt on acquisition for Valeant. It compliments Obagi Medical . Message 28788522 Valeant to acquire Solta Medical for $236 million Reuters 3 hours ago Dec 16 (Reuters) - Valeant Pharmaceuticals International said on Monday it would acquire Solta Medical Inc for about $236 million in cash, giving it access to products used in procedures such as skin rejuvenation, skin tightening and body contouring. Last month, Solta said it had retained Piper Jaffray as its adviser to explore a possible sale, in light of falling profits from its medical equipment business and pressure from activist investor Voce Capital Management LLC. Valeant would acquire all of the outstanding common stock of Solta for $2.92 per share in cash, which represents a 40 percent premium to Solta's closing share price on Dec. 13. The deal is expected to close in the first quarter of 2014. "The acquisition of Solta will bring tremendous value to Valeant's current aesthetic portfolio and together with our previous acquisitions, will create the broadest aesthetic portfolio in the industry," said Valeant Chief Executive Michael Pearson, in a statement. finance.yahoo.com